 INmune Bio, Inc. INMB the Company, an immunology company developing treatments that harness the patients innate immune system to fight disease, announced the initiation of a therapeutic program to treat patients with pulmonary complications from COVID-19 infection with its dominant-negative TNF inhibitor DN-TNF platform. Management will host a conference call on April 20th, 2020 at 4:15 PM ET to discuss the science and strategy behind its DN-TNF platform and its decision to begin the new clinical trial. 